Lysis inhibition by tranexamic acid in vitro and in vivo

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015269

Enrollment

Registered

2018-08-17

Start date

2018-09-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

test for point-of-care diagnostics (visco-elastic methods) D68

Interventions

Group 1: in-vitro: Different doses of tranexam acid in blood of healthy volunteers: (2,5mg/kg, 5mg/kg, 10mg/kg, 15mg/kg and 20mg/kg). 20ml blood withdrawal from healthy volunteers. Measurement of the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 18 years No coagulation disorder No anticoagulatory medication

Exclusion criteria

Exclusion criteria: Age < 18 Years Anticoagulants Coaguation disorder

Design outcomes

Primary

Measure	Time frame
in-vitro: Change of lysis time (LT) in viscoelastic test. Measurement for every concentration. in-vivo: Change of lysis time (LT) in viscoelastic test. Measurement after every withdraw of blood.	—

Secondary

Measure	Time frame
in-vivo: blood loss at end of surgery	—

Countries

Germany

Contacts

Public ContactSimon Schäfer

Klinik für Anästhesiologie, Klinikum der Universität München, LMU München

simon.schaefer@med.uni-muenchen.de089440081142

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026